Filtered By:
Condition: Thrombosis
Drug: Lovenox

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 54 results found since Jan 2013.

Heparins – DOACS – VKA
Patients with cancer are at increased risk of venous thromboembolism (VTE). At the same time they have often an underlying bleeding risk. That can often make decisions surrounding the administration of anticoagulants complicate. Individual risk-benefit calculation is necessary. During hospital stage the patients get, if there are no contraindications, a medical VTE prophylaxis with low molecular weight heparin (LMWH). Whereas outpatients don`t get a prophylaxis because they are at low risk of thromboembolism. If additional risk factor for VTE exists a decision for medical VTE prophylaxis should be taken into account. In pa...
Source: Phlebologie - December 2, 2015 Category: Surgery Source Type: research

Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options
Abstract The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants used for the long-term treatment or prevention of venous thromboembolism or stroke in patients with atrial fibrillation. The coagulopathy induced by VKAs can be reversed with vitamin K, and in urgent situations, the vitamin K-dependent coagulation factors can be replaced by transfusion. In the last decade, a new class of oral anticoagulants has been developed, direct oral anticoagulants that bind to a specific coagulation factor and neutralize it. These compounds were shown to be effective and safe compared with the VKA...
Source: American Journal of Cardiovascular Drugs - February 12, 2016 Category: Cardiology Source Type: research

Pharmacological Prophylaxis for Venous Thromboembolism Among Hospitalized Patients With Acute Medical Illness: An Electronic Medical Records Study
The objectives of this study were to examine pharmacological prophylaxis against VTE among hospitalized medically ill patients and to assess demographic and clinical correlates related to VTE prophylaxis. A retrospective (1999–2010) electronic medical records study included patients aged 40 years and older hospitalized for at least 3 days, with significant medical illness or with a VTE hospitalization 30–365 days before admission. Each patient's first qualifying hospitalization was analyzed. Exclusions were if VTE treatment was started within 1 day of admission, or if warfarin (and not heparin or enoxaparin) was used. ...
Source: American Journal of Therapeutics - March 1, 2016 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Id: 41: thrombotic ramifications of ophthalmologic diagnosis of familial and acquired thrombophilia as pathoetiology for otherwise unexplained uveitis.
Conclusion When the usual pathoetiologies of uveitis are not found, ophthalmologists should screen for thrombophilia, often being the first to illuminate treatable etiologies for other thrombotic events. In our 3 patients, when the pathoetiology of uveitis could not be discerned, screening for familial and acquired thrombophilia had important therapeutic ramifications in the probands and their first degree relatives. .
Source: Journal of Investigative Medicine - March 21, 2016 Category: Research Authors: Bruce, C., Dixon, S., Glueck, C., Wang, P., Hutchins, R. Tags: Genetic [amp ] Molecular Medicine Source Type: research

Upper extremity arterial thrombus presenting at birth
We report a 36-week neonate born to a 31-year-old G2P0 woman by emergency c-section due to decreased fetal movement. The pregnancy had been uncomplicated up to that point and the mother had no significant medical history. Birth weight was 2.49 kg. Apgars were 6 and 5. Superficial skin loss and dark blue discolouration were noted along the left upper extremity and hand immediately after delivery. Fluid resuscitation and sterile saline wraps slowly improved perfusion, and the extremity pinked up over the subsequent 3 h (figure 1). She was transferred to an appropriate outside facility where Doppler ultrasound revea...
Source: Archives of Disease in Childhood - Fetal and Neonatal Edition - June 16, 2016 Category: Perinatology & Neonatology Authors: LaBore, B. P., Bedell, T. H. Tags: Journalology, Drugs: cardiovascular system, Stroke, Pregnancy, Reproductive medicine, Radiology, Clinical diagnostic tests, Radiology (diagnostics), Competing interests (ethics), Resuscitation, Trauma Images in neonatal medicine Source Type: research

Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
CONCLUSION: In this prospective registry, there were no significant differences in the rates of in-hospital MACE or major bleeding after prehospital initiation of UFH, enoxaparin or bivalirudin in patients treated by primary PCI for STEMI. PMID: 27818120 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 2, 2016 Category: Cardiology Authors: Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Cerebral Venous Sinus Thrombosis in A Patient with Sj ögren's Syndrome with Atypical Antibodies: A Case Report.
CONCLUSION: This case reports the relationship between cerebral venous sinus thrombosis and Sjögren's syndrome. It is necessary to screen autoimmune disorders in patients with cerebral venous sinus thrombosis that present with no common risk factors of venous thrombosis in order to prevent inappropriate management, and potentially adverse outcomes. PMID: 27854095 [PubMed - in process]
Source: Acta Neurologica Taiwanica - November 19, 2016 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research

Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX
The finding in patients hospitalized for acute illness was said to be"a wake-up message" that even those admitted for ischemic stroke or heart failure are at special risk for thrombosis."Heartwire from Medscape
Source: Medscape Critical Care Headlines - November 29, 2016 Category: Intensive Care Tags: Cardiology News Source Type: news

Thrombotic valvular dysfunction with transcatheter mitral interventions for postsurgical failures
ConclusionThrombotic related dysfunction post‐TMVR occurred in 15% (2/13) of patients and one patient had abnormal leaflet thickening that may have been thrombus related. Dual‐antiplatelet therapy was used in all 3 cases suggesting the possible need for oral anticoagulation postmitral valve‐in‐valve therapy. © 2017 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - February 9, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Marvin H. Eng, Adam Greenbaum, Dee Dee Wang, Janet Wyman, DNP, Heider Arjomand, Pradeep Yadav, Hassan Nemeh, Gaetano Paone, Mayra Guerrero, William O'Neill Tags: Valvular and Structural Heart Diseases Source Type: research

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin
Venous thromboembolism occurs in up to one-third of patients with primary brain tumors. Spontaneous intracranial hemorrhage (ICH) is also a frequent occurrence in these patients, but there is limited data on the safety of therapeutic anticoagulation. To determine the rate of ICH in patients treated with enoxaparin, we performed a matched, retrospective cohort study with blinded radiology review for 133 patients with high-grade glioma. After diagnosis of glioma, the cohort that received enoxaparin was 3 times more likely to develop a major ICH than those not treated with anticoagulation (14.7% vs 2.5%; P = .036; hazard rati...
Source: Blood - June 22, 2017 Category: Hematology Authors: Mantia, C., Uhlmann, E. J., Puligandla, M., Weber, G. M., Neuberg, D., Zwicker, J. I. Tags: Free Research Articles, Thrombosis and Hemostasis, Clinical Trials and Observations Source Type: research

Pulmonary embolism four days after interruption of therapy with rivaroxaban.
We report on a 58-year-old male with paroxysmal atrial fibrillation (AF) with a CHA2DS2VASC score of 4 who developed central pulmonary embolism four days after interruption of rivaroxaban because of parotid surgery. He had received 40 mg enoxaparin/d. The parotid gland was partially resected within 6 hours without blood loss. Pulmonary embolism and AF occurred on the first postoperative day. He recovered with low-molecular-weight heparin in therapeutic dosages and amiodarone and was discharged with phenprocoumon. The relevance of a rivaroxaban rebound phenomenon, manifesting as arterial embolism, stroke or venous thrombo...
Source: Hamostaseologie - August 24, 2017 Category: Hematology Authors: Stöllberger C, Göndör G Tags: Hamostaseologie Source Type: research

Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention.
Conclusion: In elective PCI, low-dose UFH with sequential enoxaparin has similar effects and safety to the UFH-only method. PMID: 29578118 [PubMed - in process]
Source: Chinese Medical Journal - March 28, 2018 Category: General Medicine Authors: Huang J, Li N, Li Z, Hou XJ, Li ZZ Tags: Chin Med J (Engl) Source Type: research

Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice
AbstractAcutely ill hospitalized medical patients remain at high thromboembolic risk for several weeks after discharge. Previous trials with extended-duration thromboprophylaxis using enoxaparin, apixaban, and rivaroxaban failed to achieve acceptable net clinical benefit, largely due to excess of major bleeding. Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio. The phase III APEX trial (N = 7513) compared a betrixaban 160 mg loading dose followed by 80 mg once daily for 35–42 days, with enoxaparin 40 mg once...
Source: Drugs - February 5, 2019 Category: Drugs & Pharmacology Source Type: research

Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Abstract DS-1040, a novel low-molecular-weight inhibitor of activated thrombin-activatable fibrinolysis inhibitor, is under development for the treatment of thromboembolic diseases including venous thromboembolism and acute ischemic stroke. Here we describe the results of 3 studies that evaluated the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects. Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-d...
Source: The Journal of Clinical Pharmacology - February 26, 2020 Category: Drugs & Pharmacology Authors: Limsakun T, Dishy V, Mendell J, Pizzagalli F, Pav J, Kochan J, Vandell AG, Rambaran C, Kobayashi F, Orihashi Y, Warren V, McPhillips P, Zhou J Tags: J Clin Pharmacol Source Type: research

Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention.
Authors: Sumaya W, Parker WAE, Judge HM, Hall IR, Orme RC, Adam Z, Richardson JD, Rothman AMK, Morgan KP, Gunn JP, Storey RF Abstract A novel enoxaparin regimen consisting of intra-arterial bolus (0.75 mg/kg) followed by intravenous infusion (0.75 mg/kg/6 hours) has been developed as a possible solution to the delayed absorption of oral P2Y12 inhibitors in opiate-treated ST-elevation myocardial infarction (STEMI) patients undergoing primary angioplasty. We aimed to study the feasibility of this regimen as an alternative to standard-of-care treatment (SOC) with unfractionated heparin ± glycoprotein IIb/IIIa antago...
Source: Platelets - June 18, 2020 Category: Hematology Tags: Platelets Source Type: research